RA Capital Management’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-2,210,145
| Closed | -$42M | – | 105 |
|
|
2021
Q4 | $42M | Sell |
2,210,145
-1,888,187
| -46% | -$49M | 0.74% | 39 |
|
|
2021
Q3 | $136M | Buy |
4,098,332
+755,589
| +23% | +$23.4M | 1.89% | 16 |
|
|
2021
Q2 | $130M | Sell |
3,342,743
-1,293,403
| -28% | -$50.8M | 2.08% | 10 |
|
|
2021
Q1 | $223M | Sell |
4,636,146
-4,049,325
| -47% | -$195M | 3.37% | 6 |
|
|
2020
Q4 | $452M | Sell |
8,685,471
-140,378
| -2% | -$4.74M | 6.32% | 2 |
|
|
2020
Q3 | $236M | Sell |
8,825,849
-3,962,608
| -31% | -$91.2M | 4.32% | 5 |
|
|
2020
Q2 | $249M | Buy |
12,788,457
+2,401,046
| +23% | +$38.7M | 4.85% | 5 |
|
|
2020
Q1 | $102M | Buy |
10,387,411
+507,088
| +5% | +$6.4M | 3.23% | 8 |
|
|
2019
Q4 | $110M | Buy |
9,880,323
+3,000,000
| +44% | +$22.8M | 3.33% | 10 |
|
|
2019
Q3 | $38.6M | Hold |
6,880,323
| – | – | 2.3% | 13 |
|
|
2019
Q2 | $59.5M | Sell |
6,880,323
-1,318,014
| -16% | -$9.96M | 3.19% | 8 |
|
|
2019
Q1 | $65.9M | Hold |
8,198,337
| – | – | 2.84% | 11 |
|
|
2018
Q4 | $33.6M | Hold |
8,198,337
| – | – | 1.96% | 16 |
|
|
2018
Q3 | $45.9M | Buy |
8,198,337
+3,919,541
| +92% | +$44.8M | 2.45% | 16 |
|
|
2018
Q2 | $56.3M | Buy |
4,278,796
+1,806,452
| +73% | +$24.8M | 3.65% | 9 |
|
|
2018
Q1 | $35.1M | Buy |
+2,472,344
| New | +$31.6M | 2.69% | 11 |
|
|
2017
Q4 | – | Sell |
-700,000
| Closed | -$8.29M | – | 30 |
|
|
2017
Q3 | $8.29M | Hold |
700,000
| – | – | 0.75% | 22 |
|
|
2017
Q2 | $7.04M | Hold |
700,000
| – | – | 0.81% | 20 |
|
|
2017
Q1 | $8.15M | Sell |
700,000
-304,314
| -30% | -$2.18M | 1% | 20 |
|
|
2016
Q4 | $4.67M | Sell |
1,004,314
-3,626,800
| -78% | -$21.3M | 0.66% | 19 |
|
|
2016
Q3 | $35.8M | Buy |
4,631,114
+99,400
| +2% | +$639K | 3.7% | 9 |
|
|
2016
Q2 | $27.5M | Hold |
4,531,714
| – | – | 3.8% | 8 |
|
|
2016
Q1 | $38.6M | Buy |
4,531,714
+1,717,935
| +61% | +$15M | 4.94% | 7 |
|
|
2015
Q4 | $33.6M | Sell |
2,813,779
-310,701
| -10% | -$3.92M | 3.32% | 6 |
|
|
2015
Q3 | $31.5M | Sell |
3,124,480
-177,733
| -5% | -$2.65M | 4.52% | 5 |
|
|
2015
Q2 | $54.8M | Buy |
3,302,213
+177,064
| +6% | +$2.8M | 5.51% | 5 |
|
|
2015
Q1 | $48.4M | Sell |
3,125,149
-225,300
| -7% | -$3.41M | 4.8% | 8 |
|
|
2014
Q4 | $53.1M | Buy |
3,350,449
+1,284,878
| +62% | +$16.7M | 5.7% | 6 |
|
|
2014
Q3 | $22M | Buy |
+2,065,571
| New | +$19.2M | 2.6% | 13 |
|
|
2013
Q4 | – | Sell |
-600,000
| Closed | -$3.02M | – | 37 |
|
|
2013
Q3 | $3.02M | Buy |
+600,000
| New | +$3.67M | 0.32% | 35 |
|
Other funds holding TGTX
MC
6CM
RA Capital Management's TGTX Position: Q1 2022 in Review
RA Capital Management sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 2,210,145 shares — an estimated $42M sold.
RA Capital Management first reported a position in TGTX in Q3 2013 and held it in 30 quarters. The position peaked at $452M in Q4 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.
- RA Capital Management reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
- RA Capital Management sold 2,210,145 TG Therapeutics shares in Q1 2022, an estimated $42M.
- RA Capital Management first reported a position in TG Therapeutics in Q3 2013 and held it in 30 quarters.
- RA Capital Management's TG Therapeutics position peaked at $452M in Q4 2020.
- 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.
Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.